MCA
NKTR icon

Mercer Capital Advisers’s Nektar Therapeutics NKTR Stock Holding History

Mercer Capital Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$63K Sell
233
-100
-30% -$24K 0.03% 135
2021
Q2 		$86K Hold
333
– – 0.04% 132
2021
Q1 		$100K Hold
333
– – 0.05% 124
2020
Q4 		$85K Hold
333
– – 0.05% 122
2020
Q3 		$83K Hold
333
– – 0.05% 121
2020
Q2 		$116K Hold
333
– – 0.07% 105
2020
Q1 		$89K Buy
+333
New +$103K 0.07% 110

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Mercer Capital Advisers's NKTR Position: Q3 2021 in Review

Mercer Capital Advisers reduced its Nektar Therapeutics (NKTR) stake by 30% in Q3 2021, selling an estimated $24K and leaving 233 shares worth $63K. The position accounts for 0.03% of the portfolio, ranked #135.

Mercer Capital Advisers first reported a position in NKTR in Q1 2020 and has held it in 7 quarters since. The position peaked at $116K in Q2 2020. 241 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

  • Mercer Capital Advisers held 233 shares of Nektar Therapeutics worth $63K as of Q3 2021.
  • Mercer Capital Advisers sold 100 Nektar Therapeutics shares in Q3 2021, an estimated $24K.
  • Nektar Therapeutics made up 0.03% of Mercer Capital Advisers's portfolio in Q3 2021, its #135 holding.
  • Mercer Capital Advisers first reported a position in Nektar Therapeutics in Q1 2020 and has held it in 7 quarters since.
  • Mercer Capital Advisers's Nektar Therapeutics position peaked at $116K in Q2 2020.
  • 241 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Mercer Capital Advisers's 13F filing for Q3 2021, filed 27 Oct 2021.